PMID- 15210400
OWN - NLM
STAT- MEDLINE
DCOM- 20040729
LR  - 20071115
IS  - 0949-2321 (Print)
IS  - 0949-2321 (Linking)
VI  - 9
IP  - 4
DP  - 2004 Apr 30
TI  - Thromboprophylaxis and early antithrombotic therapy in patients with acute 
      ischemic stroke and cerebral venous and sinus thrombosis.
PG  - 199-206
AB  - So far, neither treatment with standard unfractionated heparin (UFH) nor with 
      low-molecular-weight heparin (LMWH) has been shown to reduce mortality or to 
      improve neurological outcome in patients with acute ischemic stroke. Although a 
      reduction of early recurrent stroke has been demonstrated for the use of 
      subcutaneous UFH, this benefit was offset by a similar-sized increase in 
      hemorrhagic stroke. Double-blinded studies of LMWH have demonstrated no 
      difference between active treatment and placebo suggesting that LMWH is not 
      effective for the early secondary prevention of ischemic stroke. Although UFH and 
      LMWH may be beneficial in certain subgroups of stroke who are at high risk for 
      early stroke recurrence, these subgroups are still to be defined. Currently, 
      low-dose UFH and LMWH can only be recommended for prophylaxis of deep vein 
      thrombosis in patients with acute ischemic stroke with impaired mobility or other 
      factors determining a particular high risk of venous thromboembolism. Available 
      treatment data from controlled trials favor the use of anticoagulation as the 
      first-line therapy for patients with cerebral venous and sinus thrombosis because 
      it may reduce the risk of a fatal outcome and severe disability and does not 
      promote intracranial hemorrhage.
FAU - Busch, M
AU  - Busch M
AD  - Department of Neurology, Charite Medical School, Humboldt-University, Berlin, 
      Germany.
FAU - Masuhr, F
AU  - Masuhr F
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Eur J Med Res
JT  - European journal of medical research
JID - 9517857
RN  - 0 (Heparin, Low-Molecular-Weight)
SB  - IM
MH  - Heparin, Low-Molecular-Weight/*therapeutic use
MH  - Humans
MH  - Ischemia/complications/*drug therapy
MH  - Stroke/complications/*drug therapy
MH  - Thrombosis/*drug therapy
MH  - Time Factors
MH  - Treatment Outcome
MH  - Venous Thrombosis/complications/*drug therapy
RF  - 75
EDAT- 2004/06/24 05:00
MHDA- 2004/07/30 05:00
CRDT- 2004/06/24 05:00
PHST- 2004/06/24 05:00 [pubmed]
PHST- 2004/07/30 05:00 [medline]
PHST- 2004/06/24 05:00 [entrez]
PST - ppublish
SO  - Eur J Med Res. 2004 Apr 30;9(4):199-206.